Treatment of warts

Dermatologic Therapy

Volumn 13, Issue 3, 2000, Pages 290-304

  Berman, Brian ^a   Weinstein, Andrew ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral; Chemotherapy; Human papillomaviruses; Surgery; Warts

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ACETONE; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; BLEOMYCIN; CANTHARIDIN; CIDOFOVIR; DICHLOROACETIC ACID; DIPHENCYPRONE; FLUOROURACIL; FORMALDEHYDE; GLUTARALDEHYDE; IMIQUIMOD; IMMUNOMODULATING AGENT; KARAYA GUM; LIQUID NITROGEN; PODOPHYLLIN; PODOPHYLLOTOXIN; POLYACRYLIC ACID; RECOMBINANT GAMMA INTERFERON; RETINOIC ACID; RETINOID; SALICYLIC ACID; SQUARIC ACID DIBUTYL ESTER; STEROID; TRANS VER SAL; TRICHLOROACETIC ACID; UNINDEXED DRUG; VACCINE;

ARTICLE; CANCER; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CRYOTHERAPY; DESICCATION; DISEASE CLASSIFICATION; DRUG FORMULATION; DRUG MECHANISM; DYSPLASIA; HUMAN; LASER SURGERY; SIDE EFFECT; SKIN SURGERY; TREATMENT FAILURE; VERRUCA VULGARIS; WART VIRUS;

EID: 0033802378     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2000.00031.x     Document Type: Article

References (106)

1. Viral infections involving the skin
2. Warts
3. Warts
4. Papillomavirus and HPV typing
5. Penile verrucous carcinoma: A clinico-pathologic, human papillomavirus typing and flow cytometric analysis
6. Anogenital premalignant and malignant tumors (including Buschke-Lowenstein tumors)
7. Role of papillomavirus oncogenes in human cervical cancer: Transgenic animal studies
8. Interactions between papillomavirus proteins and tumor suppressor gene products
9. Mechanism of HPV E6 proteins in cellular transformation
10. Interactions of the human papillomavirus E7 protein with cell cycle regulators
11. Oncogenes and antioncogenes in the development of HPV associated tumors
12. In vitro expressed HPV 8 E6 protein does not bind P53
13. Guidelines of care for warts: Human papillomavirus
14. Epidermodysplasia verruciformis. Immunological and nonimmunological surveillance mechanisms: Role in tumor progression
15. Epidermodysplasia verruciformis: A model for understanding the oncogenicity of human papillomaviruses
16. Therapeutic approaches to genital warts
17. Medical therapy of genital human papilloma virus-related disease
18. Office therapy for human papillomavirus infection in nongenital sites
19. Nongenital warts: Classification and treatment options
20. Detection with the polymerase chain reaction of human papillomavirus DNA in condylomata accuminata treated in vitro with liquid nitrogen, trichloroacetic acid and podophyllin
21. Clinical and immunohistochemical responses of plantar warts to topical immunotherapy with diphenylcyclopropenone
22. The treatment of warts
23. Contact immunotherapy with squaric acid dibutyl ester for warts
24. Topical treatment of resistant warts with gluteraldehyde
25. Warts
26. Topical podofilox for treatment of condylomata acuminata in women
27. Podophyllin therapy for condyloma acuminatum
28. Treatment of verruca plana with 5% 5-fluorouracil ointment
29. Warts
30. Warts (common and flat)
31. Imiquimod: Cytokine induction and antiviral activity
32. Imiquimod applied topically: A novel immune response modifier and new class of drug
33. Mechanism of action of imiquimod
34. Self-administered topical 5% imiquimod cream for external genital warts
35. Dinitrochlorobenzene is inherently mutagenic in the presence of trace mutagenic contaminants
36. Contact immunotherapy of resistant warts
37. Treatment of multiple relapsing warts with diphencyprone
38. Common and plantar warts
39. Immunotherapy of multiple recurring warts. Reassessment of the use of squaric acid dibutylester (SADBE)
40. Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts
41. Warts
42. Treatment of plantar warts in children with a salicylic acid-podophyllin-cantharidin product
43. Cryotherapy versus podophyllin in treatment of genital warts
44. A comparison of interferon alfa-2a and podophyllin in the treatment of primary condylomata acuminata
45. A randomized trial of combination therapy with intralesional interferon alpha2b and podophyllin versus podophyllin alone for the therapy of anogenital warts
46. Podpophyllin versus scissor excision in the treatment of perianal condylomata acuminata: A prospective study
47. Treatment of external genital warts: A randomised clinical trial comparing podophyllin, cryotherapy, and electrodessication
48. Comparison between the therapeutic efficacy of 0.5% podophyllotoxin preparations and 20% podophyllin ethanol solution in condylomata acuminata
49. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata
50. Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts
51. Quercetin and kaempherol: An argument against the use of podophyllin
52. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid
53. Comparison of trichloroacetic acid and podophyllin versus podophyllin alone
54. Intralesional recombinant alfa-2a interferon for the treatment of patients with condyloma acuminatum or verruca plantaris
55. Interferon therapy for condylomata acuminata
56. Systemic interferon gamma as adjuvant therapy for refractory anogenital warts. A randomized clinical trial and meta-analysis of the available data
57. Intralesional human fibroblast interferon in common warts
58. Treatment of verrucae vulgaris with α-2 interferon
59. Verruca vulgaris. Treatment with natural interferon alfa using a needleless injector
60. Management of genital infection caused by human papillomavirus
61. Therapy of genital papillomavirus infections. Part II: Methods of treatment
62. Warts: Treatment with intralesional bleomycin
63. Treatment of plantar warts with bleomycin
64. Plantar warts yield to DNA inhibitor
65. Treatment of warts with bleomycin
66. Bleomycin: An effective treatment for warts
67. The common wart: Intralesional treatment with bleomycin sulfate
68. Intralesional treatment of warts with bleomycin
69. An assessment of methods of treating viral warts by comparative treatment trials based on a standard design
70. Reduced dose of bleomycin in the treatment of recalcitrant warts
71. Bleomycin in the treatment of recalcitrant warts
72. The treatment of resistant warts with intralesional bleomycin: A controlled clinical trial
73. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: Detection and protection
74. Absence of human papillomavirus DNA in the plume of erbium:YAG laser-treated warts
75. Failure of pulsed dye laser therapy for resistant verrucae
76. 2 laser
77. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts
78. Dermatologic surgical procedures
79. External genitalia: Treatment
80. Treatment of plantar warts by blunt dissection
81. Cimetidine therapy for recalcitrant warts in adults: Is it any better than placebo?
82. Cimetidine for herpes zoster
83. Cimetidine as an immunomodulator: Chronic mucocutaneous candidiasis as a model
84. Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia
85. Common variable immunodeficiency: A family study and therapeutic trial with cimetidine
86. Cimetidine therapy for warts: A placebo-controlled, double-blind study
87. Cimetidine therapy for multiple viral warts in children
88. Cimetidine therapy for recalcitrant warts in adults
89. Cimetidine therapy for warts in children
90. Flat and facial warts treated with fluorouracil
91. Successful treatment of disseminated facial verrucae with contact immunotherapy
92. A double blind randomized placebo controlled trial of eutectic lidocaine/prilocaine cream 5% (EMLA) for analgesia prior to cryotherapy of warts in children and adults
93. Carbon dioxide laser treatment of periungual and subungual viral warts
94. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts
95. Carbon dioxide laser treatment of resistant verrucae vulgaris: Retrospective analysis
96. Genital warts and sexual abuse in children
97. Transmission of human genital papillomavirus disease: Comparison of data from adults and children
98. Hand-genital transmission of genital warts? An analysis of prevalence data
99. Most genital warts in children should be reported as possible sexual abuse
100. Therapeutic approaches to papillomavirus infections
101. Therapeutic potential of HPMPC as an antiviral drug
102. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue
103. Topical and intralesional cidofovir: A review of pharmacology and therapeutic effects
104. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized controlled trial